Navigation Links
WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
Date:2/12/2008

NORTH BRUNSWICK, N.J., Feb. 12 /PRNewswire/ -- WellGen, Inc., a biotechnology company using nutrigenomics to discover and develop food ingredients for wellness products, today announced the appointment of Robert M. Hellauer as Chief Financial Officer.

Mr. Hellauer, 56, comes to WellGen with over thirty years of broad financial leadership in the pharmaceutical, consumer and telecommunications industries. Prior to joining WellGen, he spent six years in private equity and venture-backed environments. Mr. Hellauer's earlier experience includes senior positions at Lucent Technologies / AT&T, General Signal Corporation, and Johnson & Johnson.

Dr. Kathleen Mullinix, Chief Executive Officer of WellGen, said, "Bob joins WellGen at a strategically important period, as we emerge from our origins as a research boutique and gain traction as a commercial entity. The role of Chief Financial Officer will be critical to ensuring a successful, sustainable business as we roll out our first functional food ingredient to the marketplace and significantly expand the number of ingredients in our pipeline."

Mr. Hellauer graduated from the University of Pennsylvania, where he received a Bachelor of Science degree and a Master of Business Administration degree from The Wharton School.

About WellGen

WellGen, Inc., based in North Brunswick, NJ, is a biotechnology company that is discovering and developing products for the food, therapeutics, and dietary supplement markets, with a strategic focus on functional foods. WellGen's proprietary technology platform is a method of screening the effects of food and related substances on the expression of genes associated with human health conditions. The company has developed proprietary substances that help maintain health and reduce risk and severity for a variety of diseases. Please visit our website at http://www.wellgen.com for more information.


'/>"/>
SOURCE WellGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. WellGen, Inc. Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
2. Xenome Names Ian T. Nisbet, PhD as Chief Executive Officer
3. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
4. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
5. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
6. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
7. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
8. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
9. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
10. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
11. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):